Zurcher Kantonalbank Zurich Cantonalbank Sells 4,820 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Zurcher Kantonalbank Zurich Cantonalbank reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 14.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,123 shares of the biotechnology company’s stock after selling 4,820 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in United Therapeutics were worth $10,436,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Renaissance Technologies LLC increased its holdings in United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after purchasing an additional 22,978 shares in the last quarter. FMR LLC grew its holdings in shares of United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares during the last quarter. LSV Asset Management increased its stake in shares of United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of United Therapeutics by 4.0% in the second quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after buying an additional 22,683 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its position in United Therapeutics by 0.9% during the 3rd quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company’s stock worth $203,078,000 after buying an additional 4,869 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $960,576.75. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 127,227 shares of company stock worth $47,398,820 over the last ninety days. 11.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on UTHR shares. LADENBURG THALM/SH SH lifted their target price on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company upped their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, Jefferies Financial Group boosted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Trading Down 2.0 %

Shares of UTHR opened at $370.49 on Monday. The stock has a market capitalization of $16.54 billion, a price-to-earnings ratio of 16.27, a PEG ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The firm has a fifty day simple moving average of $367.77 and a 200 day simple moving average of $335.65.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.38 EPS. As a group, research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.